- Report
- November 2024
- 100 Pages
Global
From €5312EUR$5,950USD£4,618GBP
- Report
- October 2025
- 192 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 291 Pages
Global
From €5222EUR$5,850USD£4,541GBP
- Report
- October 2025
- 191 Pages
Global
From €5222EUR$5,850USD£4,541GBP
- Report
- September 2025
- 250 Pages
Global
From €4008EUR$4,490USD£3,485GBP
- Report
- April 2025
- 175 Pages
Global
From €4008EUR$4,490USD£3,485GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €893EUR$1,000USD£776GBP
€1116EUR$1,250USD£970GBP
- Report
- November 2024
- 150 Pages
Global
From €3437EUR$3,850USD£2,988GBP
€4330EUR$4,850USD£3,765GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,200USD£3,150GBP
- Report
- August 2025
- 180 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €893EUR$1,000USD£776GBP
€1116EUR$1,250USD£970GBP
- Report
- July 2025
- 155 Pages
Global
From €4151EUR$4,650USD£3,609GBP
- Report
- May 2025
- 150 Pages
Global
From €5312EUR$5,950USD£4,618GBP
- Report
- October 2025
- 186 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 197 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 187 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 199 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 185 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 185 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 180 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more